Loading clinical trials...
Loading clinical trials...
Reducing Residual Albuminuria in Subjects With Diabetes & Nephropathy With Atrasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety & Efficacy in Japanese Subjects
Conditions
Interventions
Atrasentan low dose group
Atrasentan high dose group
+1 more
Locations
18
Japan
Site Reference ID/Investigator# 62022
Azumino, Japan
Site Reference ID/Investigator# 58124
Chiba, Japan
Site Reference ID/Investigator# 57486
Fujisawa, Japan
Site Reference ID/Investigator# 55097
Ibaraki, Japan
Site Reference ID/Investigator# 56982
Ina, Japan
Site Reference ID/Investigator# 55093
Kawagoe, Japan
Start Date
August 1, 2011
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2012
Last Updated
August 29, 2017
NCT07241390
NCT06926660
NCT06717698
NCT07450820
NCT06306963
NCT04592640
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions